This immunogenicity risk profile was analyzed for two Nbs, (i) the NOTA-anti-HER2 Nb targeting HER2 in breast cancer, and (ii) the NOTA-anti-MMR Nb targeting tumor-associated macrophages, both currently in phase II trial as PET tracers (NCT03924466, NCT03331601, and NCT04168528). Here, ERBB2 is linked to neoplasm.